Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Rheumatology

Can You Have a Safe Pregnancy With MCTD? Risks and Planning

At a Glance

Pregnancy with mixed connective tissue disease (MCTD) can be successful, but it is high risk. The safest plan is to conceive after disease has been stable for about six months, rule out pulmonary hypertension, use pregnancy-compatible medicines, and receive close rheumatology and high-risk obstetric care.

Yes, it is possible to have a safe and successful pregnancy with Mixed Connective Tissue Disease (MCTD), but it is considered a high-risk pregnancy. “High-risk” does not mean a bad outcome is inevitable; rather, it means you will need extra monitoring from a specialized care team. Planning is the most critical factor: pregnancy is safest when your MCTD has been stable and inactive (in remission) for several months—often at least six months—before conception [1]. Because MCTD can affect multiple organs, your team should typically include your rheumatologist and a maternal-fetal medicine specialist (a high-risk obstetrician) to monitor you closely before, during, and after pregnancy [2].

Why Timing Your Pregnancy Matters

Active MCTD during pregnancy significantly increases the risk of complications for both you and your baby. Studies of MCTD pregnancies show that when the disease is active, there are substantially higher odds of premature birth and perinatal death (loss of the baby just before or after birth) [1]. Achieving stable disease before trying to conceive gives you the best chance for a healthy pregnancy. If you experience an unexpected flare-up while pregnant or have an unplanned pregnancy, do not stop your medications. Instead, contact your rheumatology and obstetrics teams immediately so they can adjust your treatment safely.

Understanding Maternal and Fetal Risks

MCTD carries specific risks that require careful, individualized monitoring throughout your pregnancy.

Maternal Risks: Women with MCTD have a higher risk of developing cardiovascular and blood pressure complications. These include preeclampsia (dangerously high blood pressure with organ strain) and gestational hypertension [1][2]. There is also an increased risk of blood clots (thromboembolic events), particularly if you have a history of clots, kidney disease, or specific antiphospholipid antibodies [1]. While the rate of cesarean delivery (C-section) is higher in MCTD pregnancies, a vaginal delivery is often possible depending on your individual obstetric situation [1].

Fetal Risks and Monitoring: Babies born to mothers with MCTD have higher rates of prematurity and intrauterine growth restriction (IUGR), meaning the baby grows slower than expected [1]. The risks of miscarriage and stillbirth are also elevated compared to the general population [2]. Because of these risks, you will likely have serial growth ultrasounds and regular fetal surveillance throughout your trimesters.

Antibodies and the Baby: Antibodies associated with MCTD can cross the placenta. While anti-U1RNP is the hallmark of MCTD and has been linked to cases of neonatal lupus (a temporary condition causing rash or blood abnormalities), the risks of permanent congenital heart block (an abnormal fetal heart rhythm) are more strongly associated with overlapping antibodies like anti-Ro/SSA and anti-La/SSB [1][2]. Your doctor will check your specific antibody profile to determine if your baby needs specialized fetal echocardiograms.

Pre-Pregnancy Checklist

Before attempting to conceive, work with your team to review the following baseline health markers:

  • Organ Assessment: Baseline checks of your blood pressure, kidney function (urine protein), liver function, and complete blood counts.
  • Cardiopulmonary Screening: Evaluation for interstitial lung disease and pulmonary hypertension (see below).
  • Antibody Profile: Testing for anti-Ro/SSA, anti-La/SSB, and antiphospholipid antibodies to guide fetal monitoring and blood-clot prevention.
  • Medication Transition: Adjusting to pregnancy-compatible medications with an agreed-upon timeline.

The Importance of Checking for Pulmonary Hypertension

One of the most critical steps before getting pregnant is to be evaluated for pulmonary hypertension (PAH), which is abnormally high blood pressure in the arteries of your lungs [3].

  • PAH is a known, severe complication of MCTD that puts extreme strain on the heart, especially during pregnancy when your blood volume naturally increases [4].
  • Established PAH makes pregnancy very dangerous; medical guidelines consider it a very high-risk condition where pregnancy is often strongly discouraged [5].
  • Before getting pregnant, your doctor will likely recommend screening tests, such as an echocardiogram (ultrasound of the heart) or pulmonary function tests [6][7].
  • Note: An echocardiogram is only a screening tool. If PAH is suspected, formal diagnosis requires a procedure called a right-heart catheterization [6]. Do not try to conceive until any suspected PAH is evaluated by a specialist.
  • If you have PAH and choose to continue a pregnancy, you require multidisciplinary care at a specialized pulmonary hypertension center with intense monitoring through delivery and the high-risk postpartum period [8].

Some MCTD medications are safe for your baby, while others can cause severe birth defects. Never stop or change your medications without your doctor’s guidance, as a sudden disease flare can be far more dangerous than taking compatible drugs [9].

Generally Compatible Options:

  • Hydroxychloroquine: Often continued to control disease and prevent flares [9][10].
  • Low-dose Glucocorticoids (Prednisone): Used if needed to control active inflammation [9].
  • Certain Immunosuppressants: Azathioprine, cyclosporine, and tacrolimus are generally considered compatible [9][10].
  • Low-Dose Aspirin: Your doctor may specifically prescribe low-dose aspirin to help prevent preeclampsia. This is safe, beneficial for high-risk pregnancies, and different from general NSAID use [9].

Medications that Must Be Avoided:

  • Methotrexate, Mycophenolate Mofetil, Leflunomide, and Cyclophosphamide: These can cause severe birth defects or miscarriage. They must be stopped and washed out of your system before attempting pregnancy [11][12]. The required washout time varies by drug—from weeks to several months—so your prescriber must create a specific timeline for you.
  • Certain PAH drugs: Endothelin-receptor antagonists (like bosentan) and riociguat are strictly contraindicated due to fetal developmental risks [13].
  • Routine NSAIDs (like Ibuprofen): Prolonged use is generally avoided, especially from 20 weeks onward, as it can cause fetal kidney issues and low amniotic fluid [9]. Short-term use earlier in pregnancy still requires a clinician’s advice.

Postpartum Care and Warning Signs

The postpartum period (after delivery) requires just as much attention as the pregnancy itself. This is a common time for MCTD to flare up, and it is the highest-risk period for women with pulmonary hypertension [14]. Your team will help you plan for medication adjustments, safe breastfeeding options, and contraception for the future.

Seek immediate emergency medical care if you experience any of these warning signs after delivery: new or severe shortness of breath, chest pain, fainting, severe headaches, visual changes, heavy bleeding, or swelling in just one leg.

Common questions in this guide

Can I have a healthy pregnancy if I have MCTD?
Yes, people with MCTD can have a successful pregnancy, but it is considered high risk and requires extra monitoring. The safest time to conceive is when the disease has been quiet and well controlled, often for at least six months. A rheumatologist and maternal-fetal medicine specialist should plan care before conception and throughout pregnancy.
Why should pulmonary hypertension be checked before pregnancy with MCTD?
Pulmonary hypertension can place severe strain on the heart when pregnancy increases blood volume, making pregnancy very dangerous. Screening may include an echocardiogram and pulmonary function tests; suspected disease needs specialist evaluation and confirmation with right-heart catheterization. Do not try to conceive until suspected pulmonary hypertension has been assessed.
What MCTD medicines are usually compatible with pregnancy?
Hydroxychloroquine, low-dose prednisone, azathioprine, cyclosporine, and tacrolimus are generally considered compatible in pregnancy when prescribed for the individual patient. A clinician may also recommend low-dose aspirin to reduce preeclampsia risk. Do not stop or change MCTD medicine on your own because a flare can also threaten pregnancy.
Which MCTD medicines must be stopped before trying to conceive?
Methotrexate, mycophenolate mofetil, leflunomide, and cyclophosphamide can cause birth defects or miscarriage and usually require discontinuation and a washout period before conception. Some pulmonary hypertension medicines, including bosentan and riociguat, are also not safe in pregnancy. The timing for stopping and switching medicines must be set by the prescribing clinician.
How can MCTD affect my baby during pregnancy?
MCTD is linked with higher risks of premature birth, slower fetal growth, miscarriage, and stillbirth. Anti-U1RNP has been associated with some cases of neonatal lupus, while anti-Ro/SSA and anti-La/SSB antibodies are more strongly linked with congenital heart block, a persistent abnormal fetal heart rhythm. Your antibody results may determine whether specialized fetal echocardiograms are recommended.
What should I expect after delivery if I have MCTD?
The weeks after delivery are an important monitoring period because MCTD can flare, and pulmonary hypertension carries particular danger after birth. Your care team should review medication changes, breastfeeding safety, and contraception. Seek emergency care for severe shortness of breath, chest pain, fainting, severe headache or vision changes, heavy bleeding, or swelling in one leg.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific baseline screening tests, such as an echocardiogram or kidney function labs, do I need to complete before trying to conceive?
  2. 2.Which of my current MCTD medications need to be stopped, and what is my personalized timeline for washing them out and transitioning to safer alternatives?
  3. 3.Based on my specific antibody profile, including anti-Ro/SSA and anti-La/SSB, will my baby need specialized fetal echocardiograms during the pregnancy?
  4. 4.How will my care be coordinated between your rheumatology clinic and my maternal-fetal medicine specialist during each trimester?
  5. 5.What are the specific warning signs of an MCTD flare versus normal pregnancy symptoms that I should watch for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Mixed connective tissue disease in pregnancy: A case series and systematic literature review.

    Tardif ML, Mahone M

    Obstetric medicine 2019; (12(1)):31-37 doi:10.1177/1753495X18793484.

    PMID: 30891090
  2. 2

    Maternal and fetal outcomes in pregnancies affected by mixed connective tissue disease.

    Zhou SY, Holden L, Colon M, et al.

    Obstetric medicine 2026; 1753495X261427244 doi:10.1177/1753495X261427244.

    PMID: 41940214
  3. 3

    Clinical presentation, course, and prognosis of patients with mixed connective tissue disease: A multicenter retrospective cohort.

    Chevalier K, Thoreau B, Michel M, et al.

    Journal of internal medicine 2024; (295(4)):532-543 doi:10.1111/joim.13752.

    PMID: 38013625
  4. 4

    Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.

    Todoroki Y, Kubo S, Nakano K, et al.

    Rheumatology (Oxford, England) 2022; (61(12)):4875-4884 doi:10.1093/rheumatology/keac165.

    PMID: 35285493
  5. 5

    When pulmonary arterial hypertension and pregnancy meet: a multidisciplinary clinical experts review.

    Dominoni M, Melito C, Schirinzi S, et al.

    Archives of gynecology and obstetrics 2024; (310(6)):2839-2852 doi:10.1007/s00404-024-07827-1.

    PMID: 39570387
  6. 6

    Pulmonary hypertension in connective tissue diseases: What every CTD specialist should know - but is afraid to ask!

    Sanges S, Sobanski V, Lamblin N, et al.

    La Revue de medecine interne 2024; (45(1)):26-40 doi:10.1016/j.revmed.2023.10.450.

    PMID: 37925256
  7. 7

    Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease.

    Li Q, Dimopoulos K, Liu T, et al.

    European journal of preventive cardiology 2019; (26(10)):1067-1076 doi:10.1177/2047487318821246.

    PMID: 30971116
  8. 8

    Management of pulmonary arterial hypertension during pregnancy.

    Krishnathasan K, Constantine A, Rafiq I, et al.

    Expert review of respiratory medicine 2023; (17(5)):413-423 doi:10.1080/17476348.2023.2210838.

    PMID: 37159412
  9. 9

    EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update.

    Rüegg L, Pluma A, Hamroun S, et al.

    Annals of the rheumatic diseases 2025; (84(6)):910-926 doi:10.1016/j.ard.2025.02.023.

    PMID: 40287311
  10. 10

    Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.

    , Silver R, Craigo S, et al.

    American journal of obstetrics and gynecology 2023; (228(3)):B41-B60 doi:10.1016/j.ajog.2022.09.001.

    PMID: 36084704
  11. 11

    [Current aspects of antirheumatic therapy in pregnancy planning, during pregnancy and breastfeeding].

    Häfeli C, Förger F

    Zeitschrift fur Rheumatologie 2021; (80(8)):716-725 doi:10.1007/s00393-021-01095-z.

    PMID: 34581874
  12. 12

    The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.

    Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al.

    Annals of the rheumatic diseases 2016; (75(5)):795-810 doi:10.1136/annrheumdis-2015-208840.

    PMID: 26888948
  13. 13

    Pregnancy in Patients with Pulmonary Arterial Hypertension in Light of New ESC Guidelines on Pulmonary Hypertension.

    Barańska-Pawełczak K, Wojciechowska C, Jacheć W

    International journal of environmental research and public health 2023; (20(5)) doi:10.3390/ijerph20054625.

    PMID: 36901635
  14. 14

    Pulmonary arterial hypertension in pregnancy-a systematic review of outcomes in the modern era.

    Low TT, Guron N, Ducas R, et al.

    Pulmonary circulation 2021; (11(2)):20458940211013671 doi:10.1177/20458940211013671.

    PMID: 34104423

This page explains pregnancy planning and risks with MCTD for educational purposes only and does not replace personalized medical advice. Consult your rheumatologist and maternal-fetal medicine specialist before changing medications or trying to conceive.

Get notified when new evidence is published on Mixed connective tissue disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.